CAMBRIDGE, Mass., May 15 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, today announced the addition of Sarah E. Nash and Steven C. Wheelwright, Ph.D., to its Board of Directors. The addition of Ms. Nash and Dr. Wheelwright brings the number of Merrimack directors to nine.
Ms. Nash most recently served as Vice Chairman of J.P. Morgan Chase & Co.'s Investment Bank where she was responsible for the firm's client relationships. Prior to these responsibilities, she was the Regional Executive and Co-Head of Investment Banking for North America at J.P. Morgan & Co. Ms. Nash serves on a number of boards including the Board of Trustees for Washington & Lee University and the Board of Trustees and the Executive Committee of New York-Presbyterian Hospital.
Dr. Wheelwright is the Baker Foundation Professor, Senior Associate Dean and Director of Publication Activities at Harvard Business School (HBS). Dr. Wheelwright rejoined the HBS faculty as a Baker Foundation Professor in 2003 and is also the Chairman of the HBS Publishing Company. Beyond HBS, Dr. Wheelwright has served as a consultant, to many leading pharmaceutical companies, advising them on operating and manufacturing challenges. He currently serves on the boards of Quantum Corporation, Zions Bank, and CheckSum, and previously served on the Board of Millennium Pharmaceuticals.
"Sarah Nash and Steven Wheelwright bring tremendous and diverse experience to our Board that will help drive our growth and future success, and we look forward to their valuable contributions," said Gary Crocker, Chairman of Merrimack Pharmaceuticals. "Sarah's proven capabilities in finance and financial transactions and Steve's deep expertise in operations and manufacturing development, especially as they relate to growth, will serve Merrimack well as we continue to advance MM-093 through late-stage clinical development and advance other products in our pipeline."
Ms. Nash and Dr. Wheelwright will be joining Board members Gary Crocker, President of Crocker Ventures, James Dresser, Chairman of the Board of Trustees of Wesleyan University and former Chief Administration Officer at the Boston Consulting Group, Gordon Fehr, former Chairman and President of Pfizer Canada, Peter Lewis, Founder and President of Wharton Equity Partners, LLC, Walter Lovenberg, Ph.D., President of Lovenberg Associates and Director at OSI Pharmaceuticals, Anthony Sinskey, Ph.D., co-Founder of Merrimack Pharmaceuticals and Professor of Microbiology in the Biology Department at MIT and Robert Mulroy, President and CEO of Merrimack Pharmaceuticals.
About Merrimack
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis or with psoriasis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company's proprietary Network Biology discovery platform, developed in concert with leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. For additional information, please visit http://www.merrimackpharma.com.
Contact: James S. Scibetta, Executive VP & CFO
617-441-1043
Merrimack Pharmaceuticals, Inc.CONTACT: James S. Scibetta, Executive VP & CFO of MerrimackPharmaceuticals, Inc., +1-617-441-1043
Web site: http://www.merrimackpharma.com/
